{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:19:51Z","timestamp":1788365991099,"version":"build-2803163510"},"reference-count":90,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In women with uterine adenomyosis, bleeding and pain can have a major impact on quality of life. There is clearly a widespread demand for effective long-term medical therapies. The objective of this narrative review was to investigate the efficacy of oral gonadotropin-releasing hormone (GnRH) antagonists in the management of uterine adenomyosis by analyzing data from two post hoc analyses of two prospective randomized trials (elagolix and relugolix), one retrospective study (relugolix) and one prospective study (linzagolix). All three GnRH oral antagonists were able to control the disease and uterine fibroid-related heavy menstrual bleeding, enhancing quality of life. When administered without add-back therapy, high doses of GnRH antagonists were found to significantly and rapidly reduce uterine volume and the severity of adenomyotic lesions. Nevertheless, some limitations should be addressed. The post hoc analyses were a retrospective look at two prospective randomized clinical trials. In the elagolix study, most women underwent both transvaginal ultrasound and magnetic resonance imaging (MRI). Some who opted out of MRI may have had concurrent adenomyosis that was undetected by ultrasound, so they were not included in the adenomyosis subset. In the relugolix study, baseline ultrasounds were not specifically performed to spot adenomyosis that may have been overlooked in case of large fibroids, as shadowing can partially or completely obscure the disease. While the linzagolix study is prospective and evaluates data from women with proven adenomyosis documented by MRI, the number of cases is limited and randomized controlled trials are needed to confirm and validate this concept.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lay summary<\/jats:title>\n                    <jats:p>Uterine adenomyosis is characterized by the presence of endometrial glands inside the myometrium, the muscular layer of the uterus. Transvaginal ultrasound and magnetic resonance imaging now facilitate its diagnosis. The estimated prevalence of adenomyosis among patients of reproductive age is 20\u201330%. Rising rates in younger patients combined with a growing trend to postpone first pregnancy underscore the importance of understanding the mechanisms behind its development. We need novel strategies for the treatment of typical but distressing symptoms of adenomyosis, which include pelvic pain, abnormal uterine bleeding, menstrual cramps, painful sex and infertility. There is a lack of approved pharmacological agents specifically indicated for the treatment of adenomyosis, presenting a clear unmet need in this population. Oral gonadotropin-releasing hormone (GnRH) antagonists have recently emerged as a promising new therapeutic option. Their advantages over GnRH agonist depot formulations include an absence of the flare-up effect, hence avoiding initially worsening symptoms and rapid reversibility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/raf-26-0075","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:29:38Z","timestamp":1786714178000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-13","source":"Crossref","is-referenced-by-count":0,"title":["Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review"],"prefix":"10.1530","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2528-206X","authenticated-orcid":true,"given":"Jacques","family":"Donnez","sequence":"first","affiliation":[{"name":"Department of Gynecology, Universit\u00e9 Catholique de Louvain 1 , ,","place":["Brussels, Belgium"]},{"name":"Department of Gynecology, Soci\u00e9t\u00e9 de Recherche pour l\u2019Infertilit\u00e9 (SRI) 2 , ,","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Donnez","sequence":"additional","affiliation":[{"name":"Centre de l\u2019Endom\u00e9triose Complexe, Chirurgie Endoscopique Pelvienne, Polyclinique Urbain V (ELSAN Group) 3 , ,","place":["Avignon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh S","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine 4 , , ,","place":["New Haven, Connecticut, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Petraglia","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, Department of Clinical Experimental and Biomedical Sciences, University of Florence 5 , ,","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9656-493X","authenticated-orcid":true,"given":"Andrew W","family":"Horne","sequence":"additional","affiliation":[{"name":"EXPPECT Edinburgh Centre for Reproductive Health, University of Edinburgh 6 , ,","place":["Edinburgh, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M","family":"Becker","sequence":"additional","affiliation":[{"name":"Endometriosis CaRe Centre, Nuffield Department of Obstetrics and Gynaecology, University of Oxford 7 , ,","place":["Oxford, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan P","family":"Renner","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Hospital B\u00f6blingen 8 , ,","place":["Sindelfingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marionna","family":"Rius","sequence":"additional","affiliation":[{"name":"Endometriosis Unit, Hospital Clinic of Barcelona, University of Barcelona 9 , ,","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Bestel","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Theramex 10 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Anna","family":"Stratopoulou","sequence":"additional","affiliation":[{"name":"Gynecology Research Laboratory, Institut de Recherche Exp\u00e9rimentale et Clinique, Department of Gynecology, Universit\u00e9 Catholique de Louvain 11 , ,","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-3026","authenticated-orcid":true,"given":"Marie-Madeleine","family":"Dolmans","sequence":"additional","affiliation":[{"name":"Gynecology Research Laboratory, Institut de Recherche Exp\u00e9rimentale et Clinique, Department of Gynecology, Universit\u00e9 Catholique de Louvain 11 , ,","place":["Brussels, Belgium"]},{"name":"Gynecology Department, Cliniques Universitaires St-Luc 12 , ,","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026090211465403300_bib1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with Relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090211465403300_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jogoh.2024.102795","article-title":"The use of dienogest in treatment of symptomatic adenomyosis: a systematic review and meta-analysis","volume":"53","author":"Ali","year":"2024","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2026090211465403300_bib3","first-page":"287","article-title":"Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment","volume":"43","author":"Barbieri","year":"1998","journal-title":"J Reprod Med"},{"key":"2026090211465403300_bib4","article-title":"Changes in adenomyosis following elagolix vs leuprolide treatment in a patient with pelvic pain and infertility: a case report","volume":"37","author":"Barseghyan","year":"2023","journal-title":"Case Rep Womens Health"},{"key":"2026090211465403300_bib5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.fertnstert.2018.01.024","article-title":"Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis","volume":"109","author":"Bazot","year":"2018","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/14728222.2017.1260548","article-title":"Targeting mast cells: a new way to treat endometriosis","volume":"21","author":"Binda","year":"2017","journal-title":"Expert Opin Ther Targets"},{"key":"2026090211465403300_bib7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.fertnstert.2020.06.003","article-title":"Gonadotropin-releasing hormone antagonist linzagolix: possible treatment for assisted reproduction patients presenting with adenomyosis and endometriosis?","volume":"114","author":"Borini","year":"2020","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jpag.2014.05.008","article-title":"Uterine cystic adenomyosis: a disease of younger women","volume":"28","author":"Brosens","year":"2015","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"2026090211465403300_bib9","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.fertnstert.2023.03.006","article-title":"Endometriosis and adenomyosis: shared pathophysiology","volume":"119","author":"Bulun","year":"2023","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.rbmo.2020.11.012","article-title":"Progression of adenomyosis magnetic resonance imaging features under ulipristal acetate for symptomatic fibroids","volume":"42","author":"Calderon","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"2026090211465403300_bib11","first-page":"265","article-title":"Society of endometriosis and uterine disorders forum: adenomyosis today, Paris, France, December 12, 2023","volume":"5","author":"Catherino","year":"2024","journal-title":"F S Sci"},{"key":"2026090211465403300_bib12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.fertnstert.2025.04.037","article-title":"Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2","volume":"124","author":"Catherino","year":"2025","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/humupd\/dmz049","article-title":"Diagnosing adenomyosis: an integrated clinical and imaging approach","volume":"26","author":"Chapron","year":"2020","journal-title":"Hum Reprod Update"},{"key":"2026090211465403300_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.17860","article-title":"Effect of mifepristone vs placebo for treatment of adenomyosis with pain symptoms: a randomized clinical trial","volume":"6","author":"Che","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026090211465403300_bib15","doi-asserted-by":"crossref","first-page":"8174","DOI":"10.1038\/s41598-025-93156-5","article-title":"Long-term clinical outcomes of dienogest for perimenopausal women with symptomatic adenomyosis","volume":"15","author":"Chen","year":"2025","journal-title":"Sci Rep"},{"key":"2026090211465403300_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/09513590.2018.1505846","article-title":"Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids","volume":"35","author":"Conway","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"2026090211465403300_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-0040-1719016","article-title":"Current and future medical therapies for adenomyosis","volume":"38","author":"Cope","year":"2020","journal-title":"Semin Reprod Med"},{"key":"2026090211465403300_bib18","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1148\/rg.2018180080","article-title":"Adenomyosis: a sonographic diagnosis","volume":"38","author":"Cunningham","year":"2018","journal-title":"Radiographics"},{"key":"2026090211465403300_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.rbmo.2024.104704","article-title":"Elective uterine preservation: a novel concept to tackle reproductive ageing. Fertility preservation beyond ovaries","volume":"50","author":"Di Spiezio Sardo","year":"2025","journal-title":"Reprod Biomed Online"},{"key":"2026090211465403300_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum Reprod Update"},{"key":"2026090211465403300_bib24","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.fertnstert.2020.04.017","article-title":"Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis","volume":"114","author":"Donnez","year":"2020","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib26","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/jcm10051085","article-title":"Endometriosis and medical therapy: from progestogens to progesterone resistance to GnRH antagonists: a review","volume":"10","author":"Donnez","year":"2021","journal-title":"J Clin Med"},{"key":"2026090211465403300_bib36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.fertnstert.2025.06.013","article-title":"Gonadotropin-releasing hormone antagonist in uterine adenomyosis: some light at the end of the tunnel","volume":"124","author":"Donnez","year":"2025","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.fertnstert.2017.01.013","article-title":"Partial suppression of estradiol: a new strategy in endometriosis management?","volume":"107","author":"Donnez","year":"2017","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.fertnstert.2018.01.035","article-title":"Introduction: uterine adenomyosis, another enigmatic disease of our time","volume":"109","author":"Donnez","year":"2018","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.fertnstert.2018.12.018","article-title":"What if deep endometriotic nodules and uterine adenomyosis were actually two forms of the same disease?","volume":"111","author":"Donnez","year":"2019","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.fertnstert.2020.02.114","article-title":"Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial","volume":"114","author":"Donnez","year":"2020","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib27","doi-asserted-by":"crossref","first-page":"9941","DOI":"10.3390\/ijerph18199941","article-title":"Uterine adenomyosis: from disease pathogenesis to a new medical approach using GnRH antagonists","volume":"18","author":"Donnez","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2026090211465403300_bib28","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.3390\/jcm10245794","article-title":"Uterine adenomyosis treated by Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist: a pilot study with a new 'Hit Hard First and then Maintain' regimen of administration","volume":"10","author":"Donnez","year":"2021","journal-title":"J Clin Med"},{"key":"2026090211465403300_bib29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.rbmo.2021.09.019","article-title":"Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study","volume":"44","author":"Donnez","year":"2022","journal-title":"Reprod Biomed Online"},{"key":"2026090211465403300_bib30","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(22)01475-1","article-title":"Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials","volume":"400","author":"Donnez","year":"2022","journal-title":"Lancet"},{"key":"2026090211465403300_bib31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.fertnstert.2023.07.012","article-title":"Evolution of uterine adenomyosis volume during and after GnRH antagonist (linzagolix) treatment: lessons for further clinical trials","volume":"120","author":"Donnez","year":"2023","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpobgyn.2023.102432","article-title":"Endometriosis and adenomyosis: similarities and differences","volume":"92","author":"Donnez","year":"2024","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2026090211465403300_bib33","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/humrep\/deae076","article-title":"Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, phase 3 study (EDELWEISS 3)","volume":"39","author":"Donnez","year":"2024","journal-title":"Hum Reprod"},{"key":"2026090211465403300_bib34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.fertnstert.2025.06.016","article-title":"Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study","volume":"124","author":"Donnez","year":"2025","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib35","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.fertnstert.2024.12.031","article-title":"Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: an analysis of the PRIMROSE 1 and 2 trials","volume":"123","author":"Donnez","year":"2025","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/hropen\/hoaf025","article-title":"Two-year follow-up study (PRIMROSE 3) to assess bone mineral density in subjects with uterine fibroids completing the PRIMROSE 1 and PRIMROSE 2 linzagolix trials","volume":"2025","author":"Donnez","year":"2025","journal-title":"Hum Reprod Open"},{"key":"2026090211465403300_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1571727","article-title":"Efficacy and safety of hormone therapies for treating adenomyosis-associated pelvic pain: a systematic review and network meta-analysis of randomized controlled trials","volume":"16","author":"Etrusco","year":"2025","journal-title":"Front Endocrinol"},{"key":"2026090211465403300_bib39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jmig.2021.08.023","article-title":"Ultrasound findings of adenomyosis in adolescents: type and grade of the disease","volume":"29","author":"Exacoustos","year":"2022","journal-title":"J Minim Invasive Gynecol"},{"key":"2026090211465403300_bib40","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00404-015-3755-5","article-title":"Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial","volume":"292","author":"Fawzy","year":"2015","journal-title":"Arch Gynecol Obstet"},{"key":"2026090211465403300_bib41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.fertnstert.2017.12.030","article-title":"Pathogenesis of uterine adenomyosis: invagination or metaplasia?","volume":"109","author":"Garc\u00eda-Solares","year":"2018","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib42","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/S0140-6736(22)00622-5","article-title":"Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)","volume":"399","author":"Giudice","year":"2022","journal-title":"Lancet"},{"key":"2026090211465403300_bib43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.52054\/FVVO.15.4.109","article-title":"Junctional zone thickening: an endo-myometrial unit disorder","volume":"15","author":"Gordts","year":"2023","journal-title":"Facts Views Vis Obgyn"},{"key":"2026090211465403300_bib44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/jcm9020485","article-title":"The pathogenesis of adenomyosis vis-\u00e0-vis endometriosis","volume":"9","author":"Guo","year":"2020","journal-title":"J Clin Med"},{"key":"2026090211465403300_bib45","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.rbmo.2020.01.017","article-title":"Exploring the challenges for a new classification of adenomyosis","volume":"40","author":"Habiba","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"2026090211465403300_bib46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/uog.24786","article-title":"Consensus on revised definitions of morphological uterus sonographic assessment (MUSA) features of adenomyosis: results of modified Delphi procedure","volume":"60","author":"Harmsen","year":"2022","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2026090211465403300_bib47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/uog.26117","article-title":"Uterine junctional zone and adenomyosis: comparison of MRI, transvaginal ultrasound and histology","volume":"62","author":"Harmsen","year":"2023","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2026090211465403300_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jmri.10060","article-title":"MR imaging of diffuse adenomyosis changes after GnRH analog therapy","volume":"15","author":"Imaoka","year":"2002","journal-title":"J Magn Reason Imaging"},{"key":"2026090211465403300_bib49","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1007\/s43032-022-01077-9","article-title":"Levonorgestrel releasing intrauterine system improves menorrhagia-related quality of life in patients with symptomatic adenomyosis","volume":"30","author":"Ishizawa","year":"2023","journal-title":"Reprod Sci"},{"key":"2026090211465403300_bib50","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/09513590.2021.2000961","article-title":"A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea","volume":"38","author":"Ji","year":"2022","journal-title":"Gynecol Endocrinol"},{"key":"2026090211465403300_bib51","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00404-016-4105-y","article-title":"Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis","volume":"294","author":"Lee","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"2026090211465403300_bib52","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00404-009-1191-0","article-title":"The pathophysiology of endometriosis and adenomyosis: tissue injury and repair","volume":"280","author":"Leyendecker","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"2026090211465403300_bib53","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ijgo.12887","article-title":"Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system","volume":"146","author":"Li","year":"2019","journal-title":"Int J Gynaecol Obstet"},{"key":"2026090211465403300_bib54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ejogrb.2024.12.048","article-title":"Dienogest treatment of symptomatic adenomyosis: an in-depth meta-analysis","volume":"305","author":"Lin","year":"2025","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026090211465403300_bib55","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/humrep\/dew018","article-title":"Corroborating evidence for platelet-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis","volume":"31","author":"Liu","year":"2016","journal-title":"Hum Reprod"},{"key":"2026090211465403300_bib56","article-title":"Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea","volume":"2015","author":"Marjoribanks","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026090211465403300_bib57","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.fertnstert.2011.02.051","article-title":"Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis","volume":"95","author":"Mehasseb","year":"2011","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/uog.26159","article-title":"Prevalence of adenomyosis in women with subfertility: systematic review and meta-analysis","volume":"62","author":"Mishra","year":"2023","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2026090211465403300_bib59","first-page":"338","article-title":"Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis","volume":"2","author":"Muneyyirci-Delale","year":"2021","journal-title":"F S Rep"},{"key":"2026090211465403300_bib60","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1093\/humrep\/des332","article-title":"How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic","volume":"27","author":"Naftalin","year":"2012","journal-title":"Hum Reprod"},{"key":"2026090211465403300_bib61","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/09513590.2021.1922886","article-title":"A clinical observational study on the efficacy of subcutaneous etonogestrel implants for adenomyosis in 20 patients","volume":"37","author":"Nie","year":"2021","journal-title":"Gynecol Endocrinol"},{"key":"2026090211465403300_bib62","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000024597","article-title":"Effects of Etonogestrel implants on pelvic pain and menstrual flow in women suffering from adenomyosis or endometriosis: results from a prospective, observational study","volume":"100","author":"Niu","year":"2021","journal-title":"Medicine"},{"key":"2026090211465403300_bib63","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/jog.13406","article-title":"Long-term use of dienogest in the treatment of painful symptoms in adenomyosis","volume":"43","author":"Osuga","year":"2017","journal-title":"J Obstet Gynaecol Res"},{"key":"2026090211465403300_bib64","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.fertnstert.2017.07.021","article-title":"Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study","volume":"108","author":"Osuga","year":"2017","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib65","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.fertnstert.2020.07.055","article-title":"Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study","volume":"115","author":"Osuga","year":"2021","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib66","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/rmb2.12408","article-title":"A controlled clinical trial comparing potent progestins, LNG-IUS and dienogest, for the treatment of women with adenomyosis","volume":"20","author":"Ota","year":"2021","journal-title":"Reprod Med Biol"},{"key":"2026090211465403300_bib67","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejogrb.2008.12.010","article-title":"GISE. Determinants of adenomyosis in women who underwent hysterectomy for benign gynecological conditions: results from a prospective multicentric study in Italy","volume":"143","author":"Parazzini","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026090211465403300_bib68","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/uog.14834","article-title":"Adenomyosis by transvaginal ultrasonographic features in nulligravid women without endometriosis aged 18\u201330 years: correlation with symptoms","volume":"46","author":"Pinzauti","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2026090211465403300_bib69","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.fertnstert.2019.09.037","article-title":"Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture","volume":"112","author":"Sauerbrun-Cutler","year":"2019","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib70","doi-asserted-by":"crossref","first-page":"320.e1","DOI":"10.1016\/j.ajog.2022.11.1278","article-title":"Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials","volume":"228","author":"Stewart","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"2026090211465403300_bib71","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.3390\/jcm10214878","article-title":"Conservative management of uterine adenomyosis: medical vs. surgical approach","volume":"10","author":"Stratopoulou","year":"2021","journal-title":"J Clin Med"},{"key":"2026090211465403300_bib72","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.3390\/jcm10194585","article-title":"Identifying common pathogenic features in deep endometriotic nodules and uterine adenomyosis","volume":"10","author":"Stratopoulou","year":"2021","journal-title":"J Clin Med"},{"key":"2026090211465403300_bib73","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s43032-020-00361-w","article-title":"Origin and pathogenic mechanisms of uterine adenomyosis: what is known so far","volume":"28","author":"Stratopoulou","year":"2021","journal-title":"Reprod Sci"},{"key":"2026090211465403300_bib74","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.rbmo.2023.01.001","article-title":"M2 macrophages enhance endometrial cell invasiveness by promoting collective cell migration in uterine adenomyosis","volume":"46","author":"Stratopoulou","year":"2023","journal-title":"Reprod Biomed Online"},{"key":"2026090211465403300_bib75","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jmig.2015.09.018","article-title":"Adenomyosis: a clinical review of a challenging gynecologic condition","volume":"23","author":"Struble","year":"2016","journal-title":"J Minim Invasive Gynecol"},{"key":"2026090211465403300_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jogc.2025.103147","article-title":"Comparison between levonorgestrel-releasing intrauterine device and dienogest for adenomyosis: a systematic review with meta-analysis","volume":"48","author":"Su","year":"2026","journal-title":"J Obstet Gynaecol Can"},{"key":"2026090211465403300_bib77","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000002675","article-title":"Long-term outcomes of elagolix in women with endometriosis: results from two extension studies","volume":"132","author":"Surrey","year":"2018","journal-title":"Obstet Gynecol"},{"key":"2026090211465403300_bib78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2026090211465403300_bib79","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/uog.14806","article-title":"Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the morphological uterus sonographic assessment (MUSA) group","volume":"46","author":"Van den Bosch","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2026090211465403300_bib80","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.17242.1","article-title":"Recent advances in understanding and managing adenomyosis","volume":"8","author":"Vannuccini","year":"2019","journal-title":"F1000Res"},{"key":"2026090211465403300_bib81","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.fertnstert.2018.01.013","article-title":"Role of medical therapy in the management of uterine adenomyosis","volume":"109","author":"Vannuccini","year":"2018","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.rbmo.2023.103768","article-title":"Adenomyosis diagnosis among adolescents and young women with dysmenorrhoea and heavy menstrual bleeding","volume":"48","author":"Vannuccini","year":"2024","journal-title":"Reprod Biomed Online"},{"key":"2026090211465403300_bib83","doi-asserted-by":"crossref","DOI":"10.1080\/09513590.2025.2511329","article-title":"Medical treatment for adenomyosis: long term use of progestins","volume":"41","author":"Vannuccini","year":"2025","journal-title":"Gynecol Endocrinol"},{"key":"2026090211465403300_bib84","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.bpobgyn.2006.01.017","article-title":"Adenomyosis: epidemiological factors","volume":"20","author":"Vercellini","year":"2006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2026090211465403300_bib85","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.fertnstert.2016.10.022","article-title":"Estrogen-progestins and progestins for the management of endometriosis","volume":"106","author":"Vercellini","year":"2016","journal-title":"Fertil Steril"},{"key":"2026090211465403300_bib86","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1159\/000542947","article-title":"Update on medical treatment of endometriosis: new drugs or new therapeutic approaches?","volume":"90","author":"Vercellini","year":"2024","journal-title":"Gynecol Obstet Invest"},{"key":"2026090211465403300_bib87","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.3390\/jcm14134578","article-title":"Transitional lesions, one more step towards understanding the pathogenesis of adenomyosis","volume":"14","author":"Wacheul","year":"2025","journal-title":"J Clin Med"},{"key":"2026090211465403300_bib88","doi-asserted-by":"crossref","DOI":"10.1515\/med-2024-0914","article-title":"Efficacy of etonogestrel subcutaneous implants versus the levonorgestrel-releasing intrauterine system in the conservative treatment of adenomyosis","volume":"19","author":"Wei","year":"2024","journal-title":"Open Med"},{"key":"2026090211465403300_bib89","doi-asserted-by":"crossref","DOI":"10.1080\/09513590.2023.2237121","article-title":"Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix","volume":"39","author":"Yamanaka","year":"2023","journal-title":"Gynecol Endocrinol"},{"key":"2026090211465403300_bib90","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-0040-1716687","article-title":"Adenomyosis: mechanisms and pathogenesis","volume":"38","author":"Zhai","year":"2020","journal-title":"Semin Reprod Med"}],"container-title":["Reproduction and Fertility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/raf\/article-pdf\/doi\/10.1530\/RAF-26-0075\/523632\/raf-26-0075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/raf\/article-pdf\/doi\/10.1530\/RAF-26-0075\/523632\/raf-26-0075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:48:20Z","timestamp":1788364100000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/raf\/article\/7\/3\/RAF260075\/78002\/Role-of-oral-gonadotropin-releasing-hormone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1530\/raf-26-0075","relation":{},"ISSN":["2633-8386"],"issn-type":[{"value":"2633-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"RAF260075"}}